• Silexion won unconditional clearance from Germany’s BfArM to start its Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer.
• The authorization positions the company to launch the study in Germany alongside previously secured approval in Israel.
• First patient dosing is expected in the coming weeks, subject to site activation timelines.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606230840PRIMZONEFULLFEED1001209180) on June 23, 2026, and is solely responsible for the information contained therein.